Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 9/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.44 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3824517 | 0.95 | AURKA (0.57) | AURKARPS6KB1AURKBPARP1LMNA | |
| Trifluoroacetic Acid SCHEMBL2266587 | 0.93 | AURKA (0.54) | AURKARPS6KB1AURKBPARP1KCNMA1 | |
| Trifluoroacetic Acid SCHEMBL2269047 | 0.92 | AURKA (0.47) | AURKARPS6KB1AURKBPARP1KCNMA1 | |
| Trifluoroacetic Acid SCHEMBL2266473 | 0.91 | AURKA (0.49) | AURKARPS6KB1AURKBPARP1KCNMA1 | |
| Trifluoroacetic Acid SCHEMBL2267555 | 0.90 | PARP1 (0.47) | AURKARPS6KB1AURKBPARP1KCNMA1 | |
| Trifluoroacetic Acid SCHEMBL2265237 | 0.90 | AURKA (0.56) | AURKARPS6KB1AURKBPARP1KCNMA1 | |
| Trifluoroacetic Acid SCHEMBL2272491 | 0.90 | KCNMA1 (0.57) | AURKARPS6KB1AURKBPARP1CHIT1 | |
| Trifluoroacetic Acid SCHEMBL2267257 | 0.90 | AURKA (0.52) | AURKARPS6KB1AURKBPARP1KCNMA1 | |
| Trifluoroacetic Acid SCHEMBL2267560 | 0.89 | AURKA (0.49) | AURKARPS6KB1AURKBPARP1KCNMA1 | |
| Trifluoroacetic Acid SCHEMBL2267687 | 0.89 | AURKA (0.51) | AURKARPS6KB1AURKBPARP1KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989439-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2011-08-02 | — | — | US | claimed |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | US | claimed |
| US-8420824-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8410286-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-7989439-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2011-08-02 | — | — | US | disclosed |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | AURKA 693/4885RPS6KB1 422/4885AURKB 645/4885 |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | CYP4B1, ADORA1, CYP1B1 | AURKA 719/4885RPS6KB1 310/4885AURKB 715/4885 |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | AURKA 693/4885RPS6KB1 422/4885AURKB 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.